- This Small Biotech Rival To J&J Just Rocketed 44% Investor’s Business Daily
- Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC OncLive
- CG Oncology’s Bladder Cancer Drug Impresses Investors – Here’s Why Benzinga
- Cretostimogene yields high CR rate in BCG-unresponsive NMIBC Urology Times
- CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting TipRanks